ViewRay Announces Participation in the B. Riley Oncology Investor Conference
ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the B. Riley Oncology Investor Conference scheduled for January 20, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the B. Riley Oncology Investor Conference scheduled for January 20, 2021. Management will engage in a fireside chat and will hold one-on-one meetings with investors. An audio recording of the chat will be accessible for seven days post-event on the company’s investor website. ViewRay is known for its MRIdian® radiation therapy system, featuring advanced MR imaging specifically designed for radiation oncology to overcome challenges like beam distortion and skin toxicity.
Positive
- Participation in B. Riley Oncology Investor Conference could enhance investor visibility.
- 1x1 meetings with investors may attract potential investment opportunities.
Negative
- None.
Details
News Market Reaction – VRAY
The recorded move for VRAY in the trading session of this news was -9.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, Jan. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in a fireside chat at the B. Riley Oncology Investor Conference on Wednesday, January 20, 2021. ViewRay will also be hosting 1x1 meetings with investors.
An audio recording of the fireside chat will be available after the event on the "Financial Events and Webinars" portion of ViewRay's investor website at https://investors.viewray.com/events-and-presentations/upcoming-events. The recording will be available for 7 days after the date of the presentation.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
View original content:http://www.prnewswire.com/news-releases/viewray-announces-participation-in-the-b-riley-oncology-investor-conference-301209021.html
SOURCE ViewRay, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.